These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 12669742

  • 1. Alendronate in the treatment of Paget's disease of bone.
    Reid IR, Siris E.
    Int J Clin Pract Suppl; 1999 Apr; 101():62-6. PubMed ID: 12669742
    [Abstract] [Full Text] [Related]

  • 2. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP, Ward LC, Stewart GO, Will RK, Criddle RA, Prince RL, Stuckey BG, Dhaliwal SS, Bhagat CI, Retallack RW, Kent GN, Drury PJ, Vasikaran S, Gutteridge DH.
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [Abstract] [Full Text] [Related]

  • 3. Effects of five daily 1 h infusions of alendronate in Paget's disease of bone.
    O'Doherty DP, Gertz BJ, Tindale W, Sciberras DG, Survill TT, Kanis JA.
    J Bone Miner Res; 1992 Jan; 7(1):81-7. PubMed ID: 1549961
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Paget's disease of bone: experience from a centre in southern India.
    Anjali, Thomas N, Rajaratnam S, Shanthly N, Oommen R, Seshadri MS.
    J Assoc Physicians India; 2006 Jul; 54():525-9. PubMed ID: 17089899
    [Abstract] [Full Text] [Related]

  • 8. The antifracture efficacy of alendronate.
    Seeman E.
    Int J Clin Pract Suppl; 1999 Apr; 101():40-5. PubMed ID: 12675021
    [Abstract] [Full Text] [Related]

  • 9. The effect of 1 alpha-hydroxyvitamin D3 on the mineralization defect in disodium etidronate-treated Paget's disease--a double-blind randomized clinical study.
    Ralston SH, Boyce BF, Cowan RA, Fogelman I, Smith ML, Jenkins A, Boyle IT.
    J Bone Miner Res; 1987 Feb; 2(1):5-12. PubMed ID: 3137773
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Alendronate in the treatment of Paget's disease of bone.
    Khan SA, Vasikaran S, McCloskey EV, Benéton MN, Rogers S, Coulton L, Orgee J, Coombes G, Kanis JA.
    Bone; 1997 Mar; 20(3):263-71. PubMed ID: 9071478
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Management of Paget's disease of bone.
    Langston AL, Ralston SH.
    Rheumatology (Oxford); 2004 Aug; 43(8):955-9. PubMed ID: 15187244
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treatment of Paget's disease of bone with alendronate.
    Lombardi A.
    Bone; 1999 May; 24(5 Suppl):59S-61S. PubMed ID: 10321931
    [Abstract] [Full Text] [Related]

  • 17. The effects of alendronate on bone turnover and bone quality.
    Meunier PJ, Arlot M, Chavassieux P, Yates AJ.
    Int J Clin Pract Suppl; 1999 Apr; 101():14-7. PubMed ID: 12669736
    [Abstract] [Full Text] [Related]

  • 18. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis.
    Guañabens N, Parés A, Ros I, Alvarez L, Pons F, Caballería L, Monegal A, Martínez de Osaba MJ, Roca M, Peris P, Rodés J.
    Am J Gastroenterol; 2003 Oct; 98(10):2268-74. PubMed ID: 14572578
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.